Skip to main content
DHR logo

Danaher Corporation (DHR) Stock: Price, Forecast & Analyst Target

Danaher Corporation (DHR) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $227.56 (-0.45%), as of the Nov 19, 2026 trading session; market cap $160B. Expected results Jan 27, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$227.56 −$1.02 (-0.45%) Market Cap $160B

Danaher Corporation · DHR · NYSE · Healthcare · Medical - Diagnostics & Research

Research dated 2026-09-12: Danaher sells laboratory, bioprocessing, diagnostic and applied-analysis systems, then supplies many of the reagents, consumables and services those workflows continue to require. Revenue has resumed growth, but the case now depends on whether that recovery can produce durable operating leverage while substantial debt remains ahead of liquid resources.

Price as of Nov 19, 2026

Key Statistics

71 of 100

MoonshotScore v2 · Danaher (DHR)

Strong
Business Quality Elite (81)
Financial Safety Okay (50)
Valuation Full (47)
Growth Durability Flat (45)
Momentum Surging (87)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Jan 27, 2027
  • Altman Z 3.72 · Piotroski F 7

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DHR (57 recorded, newest six shown)
RecordedScoreBand
70Strong
70Strong
70Strong
70Strong
71Strong
71Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$227.56
Change on the day-0.45%
52-week range$160.93–$242.80
Market capitalisation$160B—
Price / earnings (trailing)36.89
Shares traded on the day4.06M
Beta (volatility vs the S&P 500)0.8

Why Danaher scores 71

Dr. Mira Sol, the Stock Expert AI TV data character
Momentum carries the score; Growth Durability is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
71Strong
  • Business Quality81
  • Financial Safety50
  • Valuation47
  • Growth Durability45
  • Momentum87

Share price, last 12 months +9.0%

$215.79 $235.31

What the price assumes

12.1% a year of free-cash-flow growth for ten years is what a $165.55B market value ( snapshot) asks for.

  • Price implies, next ten years12.1%
  • Free cash flow, last 5 years-0.6%
  • Revenue, last 5 years2.0%
  • Analysts' revenue path, 2026–20306.3%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $5.73B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 6.0% either way.

  1. +2.6%Jan ’24
  2. +6.1%Apr ’24
  3. +5.9%Jul ’24
  4. -5.9%Oct ’24
  5. -10.0%Jan ’25
  6. +6.1%Apr ’25
  7. +5.2%Jul ’25
  8. +4.7%Oct ’25
  9. -6.8%Jan ’26
  10. -5.9%Apr ’26
  11. -10.9%Jul ’26
  12. +2.5%Oct ’26
Next-session move EPS beat (11) EPS in line (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatIn line+2.5%+4.4%
BeatBeat-10.9%-1.0%
BeatIn line-5.9%-8.5%
BeatIn line-6.8%-6.9%
BeatIn line+4.7%+4.1%
BeatBeat+5.2%+10.0%
BeatBeat+6.1%+7.6%
In lineBeat-10.0%-14.4%
BeatBeat-5.9%-10.8%
BeatBeat+5.9%+9.7%
BeatBeat+6.1%+4.5%
BeatMiss+2.6%+6.1%

Beats have usually been rewarded — 7 of 11 drew a higher close the next session.

Our track record on this stock

Since the score went from 65 to 71 while the share price moved +5.8% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range
Band changes, newest first. “Right” means the price moved the way the change pointed over the next three months.
DateBand3 months6 monthsCall
Fair → Strong———
Strong → Fair———
Fair → Strong———

None of the 3 band changes we have recorded has been graded yet; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 72% of 43 rate it a buy; the average target sits +4.9% from the price of $227.56.
  • Last 90 days: 11 rating actions, every one a reaffirmation.
  • Our signals: Strong band; strongest pillar Momentum (87), weakest Growth Durability (45).

Here we and the crowd agree.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $162, high $238, latest $228. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $238 $162 high $238 Jan 28, 2026 · Earnings results · reported above the recorded estimate · close $2191Apr 21, 2026 · Earnings results · reported above the recorded estimate · close $1772Jul 21, 2026 · Earnings results · reported above the recorded estimate · close $1923Oct 21, 2026 · Earnings results · reported above the recorded estimate · close $2314 Oct 17, 2025 Nov 19, 2026 · $228 $209Oct 17, 2025$215Oct 31, 2025$221Nov 14, 2025$227Nov 28, 2025$226Dec 12, 2025$230Dec 26, 2025$238Jan 9, 2026$235Jan 23, 2026$217Feb 6, 2026$210Feb 20, 2026$196Mar 6, 2026$189Mar 20, 2026$191Apr 2, 2026$195Apr 17, 2026$175May 1, 2026$162May 15, 2026$183May 29, 2026$180Jun 12, 2026$196Jun 26, 2026$199Jul 10, 2026$192Jul 24, 2026$205Aug 7, 2026$219Aug 21, 2026$208Sep 4, 2026$212Sep 18, 2026$214Oct 2, 2026$229Oct 16, 2026$232Oct 30, 2026$233Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Danaher (DHR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Weak
Debt/Equity Neutral
ROE Neutral
Gross Margin Moderate

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Danaher (DHR), and what does it report?

Short answer · as of

Danaher is not simply a medical-device manufacturer: its portfolio spans research instruments, bioprocess technologies, clinical diagnostics, water analysis and packaging-quality tools. Customers range from drug developers and research institutions to hospitals, laboratories and industrial operators, so reported revenue combines capital equipment with recurring reagents, consumables, software and service demand.

The recurring category supplies most revenue, making utilization of Danaher-supported workflows as important as new instrument purchases.

2 · Latest results

What do the latest results show for Danaher (DHR)?

Latest revenue rose from both the preceding period and the comparable prior period, while reported earnings exceeded expectations and revenue also cleared consensus. Operating profit nevertheless declined: gross profit improved only slightly from the preceding period as selling and administrative expense and research spending increased, leaving less of the revenue gain to reach the bottom line. Operating cash flow strengthened, providing a cleaner sign of financial momentum than earnings alone.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$6.55B Oct 21, 2026
Latest report · revenue estimate
$6.56B Oct 21, 2026
Latest report · revenue vs estimate
Below estimate Oct 21, 2026
Latest report · EPS vs estimate
Above estimate Oct 21, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 21, 2026$6.55B$6.56B$2.1100$1.9200
Jul 21, 2026$6.26B$6.12B$1.9400$1.8500
Apr 21, 2026$5.95B$5.98B$2.0600$1.9400
Jan 28, 2026$6.84B$6.81B$2.2300$2.1600
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$0$0—
Q4 FY2025$0$0—
Q1 FY2026$0$0—
Q2 FY2026$0$0—
3 · Financial strengths and risks

What are the financial strengths and risks for Danaher (DHR)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow has exceeded capital expenditure throughout the displayed history, giving Danaher meaningful internally generated funding. Liquidity covers near-term obligations, but debt materially exceeds cash and investments, so sustained cash conversion matters more than the headline cash balance. The longer-running caution is that annual revenue stabilized before returning to growth while net income continued to recede; weaker laboratory, bioprocessing or diagnostic activity could pressure both instrument demand and the recurring consumables attached to those workflows.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 36.89 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Danaher (DHR)?

Short answer · as of

The next earnings report is expected on Jan 27, 2027.

Danaher’s scheduled earnings release needs to be read across revenue, gross profit and operating expense together: another sales increase would be less persuasive if operating profit again moved the other way. Cash conversion, capital spending and the recent decline in cash and short-term investments will show whether growth is rebuilding financial flexibility or merely absorbing it. Consensus assumes continued expansion across the forecast horizon, so recurring revenue and demand from biopharmaceutical, research and diagnostic customers are the operating checks behind that expectation.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Danaher compare with its peers?

Short answer

Danaher's score ranks tied for 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Unlike a focused diagnostics or laboratory-instrument business, Danaher combines life-science research, bioprocessing, clinical testing and applied industrial analysis within one portfolio. Its economic distinction is the pairing of sophisticated systems with reagents, consumables, software and services used after placement; the recurring revenue category is far larger than the nonrecurring category. That mix spreads demand across laboratories, drug manufacturers, hospitals and industrial customers, while leaving performance tied to activity across several specialized workflows rather than a single product cycle.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
IDEXX Laboratories, Inc. (IDXX) Same industry, near in market value$689.65 Nov 19, 2026$54.3B96 5-pillar Nov 18, 2026
Intuitive Surgical, Inc. (ISRG) Named competitor$420.95 Nov 18, 2026$146B94 5-pillar Nov 18, 2026
Mettler-Toledo International Inc. (MTD) Same industry, near in market value$1705.66 Nov 19, 2026$33.9B93 5-pillar Nov 18, 2026
Sanofi (SNY) Named competitor$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Same industry, near in market value$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Same industry, near in market value$175.34 Nov 19, 2026$49.4B83 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Same industry, near in market value$258.99 Nov 19, 2026$28.5B74 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Danaher (DHR) — this page$227.56$160B71
IQVIA Holdings Inc. (IQV) Same industry, near in market value$257.84 Nov 18, 2026$42.5B71 5-pillar Nov 18, 2026
Labcorp Holdings Inc. (LH) Same industry, near in market value$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026
Thermo Fisher Scientific Inc. (TMO) Same industry, near in market value$688.75 Nov 19, 2026$255B70 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$195.00 – $275.00
Consensus target
$244.63
Median target
$250.00

Consensus record · Captured .

Measured against a quoted price of $227.56 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 9, 2026

Transactions
50
Identified insiders
18
Purchases
0
Sales
9
Other transactions
41

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DHR in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Tiger GlobalChase ColemanQ3 20261.39%$281.10MAdded +178.2% shares
Viking GlobalAndreas HalvorsenQ3 20260.71%$231.20MNew position
Bridgewater AssociatesFounded by Ray DalioQ3 20260.38%$87.79MAdded +1442.7% shares
Gates Foundation TrustBill & Melinda Gates FoundationQ3 20260.28%$82.64MHeld, unchanged
Third PointDan LoebQ3 20260%$0Sold out (was $102.86M)
Duquesne Family OfficeStanley DruckenmillerQ3 20260%$0Sold out (was $9.58M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Danaher (DHR)?

Read these with our analysis →

DHR Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

What makes Danaher’s revenue recurring?

Danaher sells reagents, consumables, software and services alongside instruments used in bioprocessing, laboratory research, clinical diagnostics and applied analysis. Those continuing purchases account for most reported revenue.

Why can Danaher’s revenue rise while operating profit falls?

In the latest period, gross profit improved only modestly from the preceding period while selling and administrative expense and research spending rose. The added operating expense more than absorbed the gross-profit increase.

Which customers drive Danaher’s Life Sciences demand?

Pharmaceutical and biopharmaceutical companies, universities, medical schools, research institutions and industrial manufacturers buy Danaher’s research instruments, genomics tools, bioprocess systems and related consumables. Their research and production activity influences both equipment purchases and continuing workflow demand.

How exposed is Danaher to debt despite its cash generation?

Debt remains well above cash and investments, despite operating cash flow consistently covering capital expenditure. That makes continued cash conversion central to preserving flexibility.

What is the DHR stock price today?

The last price recorded for Danaher Corporation (DHR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DHR price target?

The analyst consensus price target for Danaher Corporation (DHR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Danaher (DHR), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Danaher (DHR)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Danaher (DHR)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash against market value; Trailing twelve-month ratio set; Annual revenue and net result (USD millions); Business description
  • 4. What should you watch next at Danaher (DHR)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Revenue by segment; Business description
  • 5. How does Danaher compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: What makes Danaher’s revenue recurring?: Business description; Revenue by segment
  • FAQ: Why can Danaher’s revenue rise while operating profit falls?: Quarterly income statement (USD thousands)
  • FAQ: Which customers drive Danaher’s Life Sciences demand?: Business description; Revenue by segment
  • FAQ: How exposed is Danaher to debt despite its cash generation?: Cash, investments and debt; Cash and investment components; Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold DHR

Funds in our ETF coverage that list DHR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
FM Focus Equity ETF (FMCX)4.33%
Madison Covered Call ETF (CVRD)4.18%